Guobang Pharma Ltd.

605507

CNE100004NS2

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 31/05/2024 am IST			5-day change	1st Jan Change
17.93 ^CNY	-0.22%		-0.72%	+2.11%

15/04	Guobang Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
27/01	Guobang Pharma Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.	CI

Guobang Pharma Ltd. has filed an IPO.

October 30, 2020 at 09:30 am IST

Guobang Pharma Ltd. has filed an IPO. Security Name: A shares Security Type: Common Stock Securities Offered: 83,823,500

Latest news about Guobang Pharma Ltd.

Guobang Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/04	CI
Guobang Pharma Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.	27/01	CI
Guobang Pharma Ltd. authorizes a Buyback Plan.	26/01	CI
Hangzhou Shenshi Energy Conservation Technology Co.,Ltd announced that it has received CNY 200 million in funding from Zhejiang Yinxinggu Investment Co, Ltd., Guobang Pharma Ltd., Beiqi Foton Motor Co.,Ltd., China V Fund Management Co., Ltd., Gold Stone Investment Co., Ltd. and other investors.	20/11	CI
Guobang Pharma Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	18/23/18	CI
Guobang Pharma Ltd.(XSSC:605507) added to S&P Global BMI Index	18/23/18	CI
Guobang Pharma Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	27/23/27	CI
Guobang Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	14/23/14	CI
Guobang Pharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	09/23/09	CI
Guobang Pharma Unit Passes Administrative Inspection	23/22/23	MT
Guobang Pharma Ltd.(SHSE:605507) dropped from Shanghai Stock Exchange Health Care Sector Index	09/22/09	CI
Guobang Pharma Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	18/22/18	CI
Guobang Pharma Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	17/22/17	CI
Guobang Pharma Ltd.(SHSE:605507) added to Shanghai Stock Exchange Composite Index	02/22/02	CI
Guobang Pharma Ltd.(SHSE:605507) added to Shanghai Stock Exchange A Share Index	02/22/02	CI
Guobang Pharma Ltd.(SHSE:605507) added to Shanghai Stock Exchange Health Care Sector Index	13/22/13	CI
Guobang Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	27/22/27	CI
Guobang Pharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	15/22/15	CI
COVID-19 rattles major Chinese manufacturing province	14/21/14	RE
Guobang Pharma Ltd. has completed an IPO in the amount of CNY 2.730131 billion.	28/21/28	CI
Guobang Pharma Ltd. has filed an IPO.	30/20/30	CI

Guobang Pharma Ltd is a China-based company mainly engaged in the research and development, production, and sales of related products in the field of medicine and animal health products. The Company's pharmaceutical business includes raw materials, key pharmaceutical intermediates and preparations, and its main products include azithromycin, clarithromycin, and roxithromycin cephalosporin series products. The animal health products business includes animal protection raw materials, animal protection additives and preparations. The main products of veterinary antibiotics include florfenicol, enrofloxacin series, etc., and insecticides include diclazuril and cypronamine, and reparation products include premixes, powders, granules, etc.

Sector

Pharmaceuticals

Calendar

19/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Guobang Pharma Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

17.93 CNY

Average target price

23 CNY

Spread / Average Target

+28.28%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GUOBANG PHARMA LTD.	+2.11%	1.38B
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B
PFIZER, INC.	-0.45%	162B

Other Pharmaceuticals